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Abstract: 
Leukemia is the most common malignancy of child-
hood representing about 30 % of oncohematological 
diseases diagnosed in children less than 15 years of 
age. We report the case of a 4 year old girl with acute 
promyelocytic  leukemia  whose  blasts  showed  the 
morphology  characteristic  of  acute  promyelocytic 
leukemia variant. The case is reported because in the 
paediatric population the acute promyelocytic leuke-
mia is a rare occurrence moreover, it represent a true 
oncohematology emergency, in this case the labora-
tory has a significant role since the timing of diagnosis 
must be very short. It helps in therapeutic protocols 
compared  to  conventional  therapeutic  protocols  in 
Acute Myeloid Leukemia (AML), the introduction of 
retinoid  All-Trans-Retinoic  Acid  (ATRA),  both  in 
children and adults with Acute Promyelocytic Leuke-
mia (APL), has significantly reduced the early mortal-
ity.
Keywords: Acute Promyelocytic  Leukemia (APL), 
All-Trans-Retinoic Acid (ATRA), Leukemia, Oncohe-
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Introduction:
Leukemia  is  the  most  common  malignancy  of 
childhood representing about 30 % of oncohema-
tological diseases diagnosed in children less than 
15  years  of  age.  In  childhood  most  cases  of 
leukemia are acute leukemia and are characterized 
essentially by the lymphoid B-population involve-
  ment  [1]. Acute  myeloid  leukemia  (AML)  in 
paediatric field represents the 15-20 % and the 
related  mortality  is  approximately  30  %. 
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AML incidence in children is about 5-7 cases per 
million children year, the incidence peak is 11 
cases per million in children under two years of 
  age [1]. AML incidence is very low at around 9 
years of age during adolescence it is 9 cases per 
million approximately. Between paediatric AML 
the incidence of acute promyelocytic leukemia 
(APL) is <10% [1]. In a multicenter Italian study, 
the APL was diagnosed in approximately 30 % of 
paediatric AML. As part of the AML, APL repre-
sents a distinct subtype that affects the treatment 
significantly. 
Differentiation therapy of APL has subsequently 
undergone further refinements and results from 
2007 show that up-front use of ATRA/ATO plus 
induction  chemotherapy  leads  to  complete 
remission  rates  in  excess  of  93  %  with  these 
patients  achieving  5-year  overall  survival  rates 
approaching 100 %. The majority of AML cases 
are characterized by specific single chromosomal 
alterations encoding leukemogenic proteins that 
function as constitutive transcriptional repressors 
of differentiation and programmed cell death and 
in common with APL [1].
Case Report:
We report the case of a four-year old girl who 
arrived at the emergency room of hospital for the 
presence  of  extensive  bruising  and  petechiae 
located in the lower limbs (Fig. 1) and significant 
bleeding gums. Fig. 3: Blast with Bilobed Nucleus 
Road (Arrow)
Fig. 4: Blasts Myeloperoxidase (MPO) Positive
The presence of myeloperoxidase positive blast 
population  oriented  towards  an AML,  and  the 
distinctive morphology of the blasts give evidence 
for APL-M3.  Because  a  specialized  paediatric 
oncohematology department is not present in our 
hospital, after a few hours the patient was referred 
to another hospital and post referral follow up was 
not possible.
Discussion:
In children the APL is rare. Morphologically the 
classic APL is characterized by the presence of 
blasts promyelocytes hyper granulate > 20% with 
intracytoplasmatic auer rods that in several cases, 
for their high number, form the so-called "faggot 
cells". In the APL-M3 the blasts show abnormal 
intracytoplasmatic  granules,  the  nuclei  are 
bilobed or have a monocytoid appearance [1].
and Auer  Fig. 1: Petechiae Over Limbs
Fig. 2: Hepatosplenomegaly
The heart rate was 133/min, O  saturation 98%  2
with massive hepatosplenomegaly (Fig. 2) and 
lymphadenopathy.  The  complete  blood  count 
showed  severe  normochromic  anemia  (Hb  = 
5.4g/dl, Ht = 21%; MCHC =27g/dl) and severe 
thrombocytopenia (PLT = 0.30 lakhs/μl). There 
9 was leukocytosis (WBC = 127.9x10 /L) and the 
automatic  differential  leukocyte  count  showed 
neutrophilia (Neutrophils = 70%)
In this case given the analytical data, the morpho-
logical evaluation of peripheral blood smear is 
mandatory. The leukocytes differential count obt-
ained with light microscopy showed neutropenia 
9 (Neutrophils = 0.81x10 /L), moreover the blood 
smear showed several blasts with small and stubby 
cytoplasmatic Auer roads, nucleus often atypical 
appearance or Internuclear bridge (Fig. 3 & 4).
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were reported: APL with basophilic morphology, 
APL with M2-like blasts morphology, and APL 
with M1-like blasts morphology (early promy-
elocytic). The new WHO classification includes 
the APL between "AML with recurrent cytogene-
tic abnormalities"; other cytogenetic abnormali-
ties  and  specific  genes  involved  in  AML  are 
AML1/ETO, inv 16, and MLL. The APL variants 
genetically are uncommon and in most cases show 
the transcript PML/RARα isoform bcr 1 and bcr 2 
[2].
The immunophenotype frequently expresses the 
positivity for CD13 and CD33 antigens but does 
not express HLA-DR, CD34, and CD11b. In some 
studies the CD56 positivity at diagnosis is associ-
ated with poor outcome [1].   In our patient the 
presence  myeloblasts,  auer  rods  in  peripheral 
smear study and myeloperoxidase positive blast 
population  oriented  towards  an AML,  and  the 
distinctive morphology of the blasts give evidence 
for APL-M3. We have not performed immuno-
phenotyping and cytogenetic study.
Clinically, in children as with adults, the APL is 
characterized by a high incidence of leukocytosis 
9 (WBC >10x10 /L), as well as the APL-M3v and it 
is an important prognostic factor. In our patient 
9 count  was  127.9x10 /L.  Patients  with  WBC  > 
9 9 5x10 /L  or  >10x10 /L  generally  have  a  poor 
outcome. Furthermore, patients with leukocytosis 
at diagnosis can present positivity for FMS-like 
tyrosine kinase 3(FLT3) internal tandem duplica-
tion  (ITD)  (FLT3/ITD);  the  leukocytosis  with 
FLT3/ITD positivity represents a bad prognostic 
factor [3]. Morphologically over 25 % of paediatric 
APL appear as microgranular APL variant. About 
75% of patients at diagnosis have significant DIC 
(Disseminated  Intravascular  Coagulation)  with 
major  bleeding  events  that  impact  on  outcome. 
Compared with other AML, hepatosplenomegaly 
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and lymphadenopathy in APL are uncommon.[1] 
Our  patient  presented  with  hepatosplenomegaly 
but  lymphadenopathy  was  not  observed.  With 
regard  the  gender,  some  paediatric  therapeutic 
trials reported a slight increase of APL in females 
[1] as seen in our case. 
The APL is associated with a specific chromo-
   somal abnormality, the t (15;17) translocation [2].
The  translocation  affects  the  break  point  that 
involves the Retinoic Acid Receptor, producing a 
"Promyelocytic Leukemia (PML)" protein fusion 
with "Retinoic Acid Receptor-α (RAR-α)", the 
rearrangement forms the gene fusion PML/RAR-
α, specific marker of disease. It was not until 1980 
that various compounds, among them the retinoid 
all-trans-retinoic  acid  (ATRA),  were  found  to 
induce differentiation in an AML cell line and 
APL (but not other AML subtype) patient samples 
   [2].
Around the same time, a research group based in 
Shanghai and New York had started to screen for 
differentiation  inducers  (including  ATRA)  and 
this led to the first ATRA-based treatments in 1985 
for APL patients harbouring the t(15;17)(q22;q21) 
translocation  that  encodes  the  promyelocytic 
leukaemia (PML)/retinoic acid receptor a (RARa) 
fusion oncoprotein [3]. Although ATRA, in unpre-
cedented fashion in oncology, was able to induce 
complete remission as a single agent, all cases 
eventually relapsed. In contrast, rarely occurring 
t(11;17)-associated  APL,  which  expresses  the 
promyelocytic  leukaemia  zinc  finger 
(PLZF)/RAR-α fusion oncoprotein, is resistant to 
ATRA-  induced  differentiation  therapy  due  to 
unabated transcriptional repression[1]. 
Subsequent  incorporation  of  induction  chemo-
therapy into the treatment strategy significantly 
improved long-term patient survival. In 1992, it 
was reported that Ailing-1, a traditional Chinese 
medicine containing high levels of arsenic trioxide (ATO),  induced  dramatic  remissions  in  APL 
patients, even those that had relapsed and were 
resistant to ATRA treatment [4].
Compared to conventional therapeutic protocols in 
AML, the introduction of ATRA, both in children 
and adults with APL, has significantly reduced the 
early mortality due to bleeding. This therapeutic 
approach should not lead to misunderstanding of 
the  "Retinoic Acid  Syndrome",  also  known  as 
retinoic acid differentiation syndrome [4].
In about 80% of the paediatric cases the introduc-
tion of ATRA has led to the cure of APL [1]. The 
problem of relapse remains open. Understanding 
the  molecular  pathogenesis  of  APL  and  the 
subsequent  introduction  of  new  therapeutic 
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regimens is required for the cure of the disease. It 
is also important to understand the epidemiology 
of  the  disease  in  paediatric  field  according  to 
geography. 
Conclusion: 
Paediatric APL is uncommon. It represents a true 
emergency in oncohematology. Haematological 
laboratory plays an important role in early diagno-
sis of APL, its management and outcome. 
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